What is the CJC-1295 Ipamorelin BPC-157 TB-500 stack?

This four-compound stack combines two established sub-stacks: CJC-1295 plus Ipamorelin (the classic GH axis combination for growth hormone optimisation, body composition, and sleep) and BPC-157 plus TB-500 (the Wolverine healing stack for tissue repair, angiogenesis, and injury recovery). Together they address performance from two simultaneous angles: systemic GH axis optimisation and direct acceleration of tissue repair. No known antagonism exists between any of the four compounds.

Can you combine GH peptides with BPC-157 and TB-500?

Combining GH secretagogues (CJC-1295 and Ipamorelin) with tissue repair peptides (BPC-157 and TB-500) is commonly described in anecdotal performance research communities. There is no known pharmacological interaction or antagonism between the two sub-stacks. They operate on entirely different receptor systems and biological pathways. The combination is considered additive: GH axis optimisation supports recovery systemically, while BPC-157 and TB-500 accelerate local and systemic tissue repair.

What is the protocol for the performance and recovery stack?

Common research protocols include CJC-1295 (no-DAC) at 100 to 200 mcg per injection combined with Ipamorelin at 200 to 300 mcg per injection, administered 2 to 3 times per day subcutaneously in a fasted state. BPC-157 is used at 200 to 500 mcg per day subcutaneously, preferably near the injury site. TB-500 is used at 2 to 2.5 mg subcutaneously twice per week during a loading phase of 4 to 6 weeks, then 2 mg once per week for maintenance. GH peptides and repair peptides can be run simultaneously.

Is CJC-1295 with DAC or without DAC better for this stack?

CJC-1295 without DAC (Mod GRF 1-29) is the standard form for this stack. Without DAC, CJC-1295 has a short half-life of approximately 30 minutes, producing discrete GH pulses that mimic natural pulsatile GH release when combined with Ipamorelin in a single injection. CJC-1295 with DAC has a half-life of approximately 7 to 8 days, producing sustained continuous GHRH stimulation, which differs substantially from physiological GH secretion and requires a different dosing approach.

How long should you run the performance recovery stack?

Common cycle durations described in research accounts are 8 to 12 weeks for GH peptides (CJC-1295 and Ipamorelin), with 4 to 8 weeks off between cycles. BPC-157 is often run for shorter targeted periods of 4 to 8 weeks, particularly for specific injury recovery. TB-500 loading phase is typically 4 to 6 weeks, followed by a maintenance phase or cessation. All four compounds can be run simultaneously for the duration of the injury recovery period and GH cycle.

CJC-1295 + Ipamorelin + BPC-157 + TB-500, Performance and Recovery Stack Research Reference

The CJC-1295 + Ipamorelin + BPC-157 + TB-500 performance and recovery stack combines two of the most established peptide sub-stacks in anecdotal research communities. The CJC-1295 + Ipamorelin combination is the classic GH axis protocol, targeting growth hormone optimisation, body composition, sleep quality, and systemic recovery. The BPC-157 + TB-500 Wolverine stack targets direct tissue repair, angiogenesis, and injury recovery. Together, they address performance and recovery from two simultaneous and complementary biological angles.

Stack Overview

Parameter	Detail
Components	CJC-1295 (no-DAC) + Ipamorelin + BPC-157 + TB-500
Mechanisms	GH axis stimulation via GHRH and GHSR (CJC-1295 + Ipamorelin) + tissue repair via cytoprotection and angiogenesis (BPC-157 + TB-500)
Primary reported goal	Performance, accelerated recovery, injury healing, body composition
Category	Performance / Recovery

Research context: CJC-1295 and Ipamorelin have independent published research bases on GH stimulation. BPC-157 and TB-500 have independent animal model research on tissue repair. The four-compound combination is primarily described anecdotally. No clinical trial has studied all four compounds together. The individual two-compound sub-stacks each have their own established anecdotal research bases.

Components

Component	Class	Primary Mechanism	Standard Research Form
CJC-1295 (no-DAC)	GHRH analogue	GHRH receptor agonist, amplifies pituitary GH pulse amplitude	100 to 200 mcg per injection SubQ
Ipamorelin	GHRP / ghrelin mimetic	GHSR agonist, stimulates GH release, suppresses somatostatin	200 to 300 mcg per injection SubQ
BPC-157	Gastric pentadecapeptide	Cytoprotection, tissue and gut repair, angiogenesis, NO pathway	200 to 500 mcg per day SubQ or IM
TB-500	Thymosin Beta-4 fragment	G-actin sequestration, systemic cell migration, angiogenesis, anti-inflammation	2 to 2.5 mg twice per week SubQ or IM

For individual compound profiles, see:

For sub-stack references, see:

Commonly Reported Protocol

The following information represents commonly reported research ranges from anecdotal accounts. These are not medical recommendations.

GH Axis Protocol (CJC-1295 + Ipamorelin)

CJC-1295 (no-DAC) and Ipamorelin are typically co-administered in the same injection or in separate syringes at the same time:

Parameter	Commonly Reported Range
CJC-1295 (no-DAC) dose	100 to 200 mcg per injection
Ipamorelin dose	200 to 300 mcg per injection
Injections per day	2 to 3
Timing	Fasted state, typically morning and pre-sleep
GH cycle duration	8 to 12 weeks

Timing rationale: GH secretagogues are reported to produce larger pulses in a fasted, low-insulin state. Morning and pre-sleep injections align with natural GH pulsatility, including the large GH pulse that occurs after sleep onset.

Tissue Repair Protocol (BPC-157 + TB-500)

Parameter	Commonly Reported Range
BPC-157 dose	200 to 500 mcg per day
BPC-157 route	SubQ or IM, preferably near injury site
TB-500 loading dose	2 to 2.5 mg twice per week (weeks 1 to 4 to 6)
TB-500 maintenance dose	2 mg once per week (after loading)
Tissue repair cycle	4 to 8 weeks (BPC-157), 4 to 6 week loading plus maintenance (TB-500)

Injury-site injection: BPC-157 is sometimes described as administered at or adjacent to the specific injury site for targeted local effects, in addition to or instead of a distant subcutaneous site. TB-500 is typically administered at a standard subcutaneous site regardless of injury location due to its proposed systemic mechanism.

Combined Protocol Notes

All four compounds can be run simultaneously without reported interference
GH peptides and repair peptides are described in anecdotal accounts as mutually compatible and potentially synergistic
BPC-157 may be cycled more briefly (4 to 8 weeks targeted) while GH peptides are run longer (8 to 12 weeks)
Common off-cycle: 4 to 8 weeks off GH peptides between cycles

Reported Synergies

GH axis and tissue repair synergy: CJC-1295 + Ipamorelin stimulates GH and downstream IGF-1 production. GH and IGF-1 are known to play roles in soft tissue repair, collagen synthesis, and recovery. Adding BPC-157 and TB-500 provides direct tissue repair mechanisms operating independently of the GH axis. The combination addresses recovery through both systemic GH-mediated effects and direct tissue-level repair peptide activity.

Dual angiogenesis: BPC-157 and TB-500 both have independently researched angiogenic effects: formation of new blood vessels that improves tissue perfusion at injury sites. GH axis stimulation may also support tissue perfusion and nutrient delivery to healing tissues. The combined angiogenic and GH-mediated effects are proposed to provide comprehensive support for tissue repair.

CJC-1295 + Ipamorelin sub-stack synergy: The two GH peptides work through distinct receptors: CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin/GHSR receptor. This dual-receptor stimulation produces GH pulses proposed to be larger than either compound alone, while Ipamorelin’s somatostatin suppression removes the GH release inhibitory brake simultaneously.

BPC-157 + TB-500 sub-stack synergy: The Wolverine combination pairs local/targeted tissue repair (BPC-157 via cytoprotection and growth factor signalling) with systemic repair (TB-500 via actin modulation and cell migration). See Wolverine Stack for detailed Wolverine-specific synergy documentation.

Reported Effects

Growth Hormone Optimisation and Body Composition

The CJC-1295 + Ipamorelin component produces elevated pulsatile GH and downstream IGF-1. Anecdotal research accounts consistently describe improved body composition with extended use: reduction in body fat (particularly visceral), preservation or modest increase in lean mass, and improved recovery metrics.

Accelerated Injury and Tissue Repair

The BPC-157 + TB-500 component provides direct tissue repair acceleration. Anecdotal accounts consistently describe faster healing of tendons, ligaments, and muscle injuries. Gut health improvements are also frequently described with BPC-157.

Sleep Quality

Improved sleep quality is among the most frequently described early effects of the GH peptide component, often reported within the first 1 to 2 weeks. Pre-sleep injection timing amplifies the natural sleep-onset GH pulse.

Inflammation Reduction

TB-500’s anti-inflammatory properties and BPC-157’s cytoprotective effects are described as contributing to systemic reduction in inflammation, reduced post-exercise soreness, and improved joint comfort.

Reported Side Effects

Side Effect	Frequency Reported
Injection site redness or mild pain	Common (any SubQ or IM injection)
Water retention or mild oedema (GH effect)	Occasionally reported
Fatigue or tingling at injury site	Occasionally reported
Headache (GH peptides)	Occasionally reported
Vivid dreams (pre-sleep GH dosing)	Occasionally reported
IGF-1 elevation (expected pharmacological effect)	Universal at therapeutic doses

TB-500 oncology precaution: TB-500 has a preclinical signal for potential acceleration of dormant or latent tumour growth in animal research. Researchers with a personal or family history of cancer should carefully review this consideration before use. This concern relates to TB-500 specifically and not to the other three compounds.

WADA: TB-500 is explicitly listed as a prohibited substance under WADA anti-doping regulations. GH secretagogues are prohibited in competition. Athletes subject to anti-doping rules should review current WADA prohibitions.

Research Context

The four-compound combination is entirely anecdotal as a combined protocol in healthy human research. The individual components have the following research contexts:

CJC-1295 (no-DAC) and Ipamorelin have been studied independently and as a combination in animal and human research, primarily in the context of GH deficiency and ageing populations rather than healthy adults for performance purposes.

BPC-157 has extensive animal model research supporting tissue repair, gut healing, and cytoprotective effects. It remains in preclinical stages in Western regulatory frameworks.

TB-500 (Thymosin Beta-4 fragment) is a synthetic fragment of the naturally occurring thymosin beta-4 protein. Animal research has documented angiogenic and anti-inflammatory effects. It is prohibited by WADA.

Frequently Asked Questions

Can all four compounds be injected at the same time? Anecdotal research accounts describe the GH peptides (CJC-1295 + Ipamorelin) in one injection and BPC-157 in a separate injection, sometimes at different sites. TB-500 is typically a separate injection at a standard subcutaneous site. Combining all four in one syringe is not commonly described due to volume and compatibility considerations.

Is CJC-1295 with DAC suitable for this stack? CJC-1295 with DAC (Drug Affinity Complex) has a half-life of approximately 7 to 8 days, providing sustained GHRH receptor stimulation rather than discrete pulses. This is a different pharmacological profile from the no-DAC form. With DAC, the dosing schedule changes to once or twice per week, and it is not typically combined with Ipamorelin in the same injection. Most accounts for this four-compound stack use the no-DAC form for its pulse-mimicking pattern.

How does this stack relate to the Wolverine and CJC-1295 + Ipamorelin stacks? This stack is the union of two established sub-stacks. The CJC-1295 + Ipamorelin stack covers GH axis optimisation. The Wolverine stack covers BPC-157 + TB-500 tissue repair. Combining them adds GH-mediated systemic recovery support to the direct tissue repair of the Wolverine combination. Individual stack pages should be reviewed as the primary protocol reference for each sub-stack.

Do BPC-157 or TB-500 interfere with GH peptide effects? No pharmacological interaction between GH secretagogues and tissue repair peptides has been identified in research or anecdotal accounts. They operate on distinct biological pathways and receptor systems with no known overlap that would cause antagonism or interference.

CJC-1295 + Ipamorelin, GH axis sub-stack reference
Wolverine, BPC-157 + TB-500, tissue repair sub-stack reference
GLOW, BPC-157 + TB-500 + GHK-Cu, adds skin and collagen support
KLOW, BPC-157 + TB-500 + GHK-Cu + KPV, comprehensive healing extension